In addition, the use of siRNAs and the chemical antagonist CCX771 have been explored to target CXCR7 in gliomas, inhibiting the phosphorylation of ERK1/2 and obtaining similar results as when targeting CXCR4, although further research needs to be performed regarding CXCR7 inhibitors [213]. The gene discussed is CXCR4; the disease is glioma.